First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial - Top-Institutions - MDSpire

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

  • By

  • Peter Schmid

  • Seock-Ah Im

  • Zbigniew Nowecki

  • Piotr J. Wysocki

  • Jacek Jassem

  • Kyung Hae Jung

  • Simon Lord

  • Jon Armstrong

  • Ross Stewart

  • Petra Vuković

  • Neelima Denduluri

  • Yeon Hee Park

  • June 8, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    BEGONIA
    BEGONIA

    N/A, N/A

    Key Differentiators

    • Oncology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #3

    German Breast Group
    German Breast Group

    N/A, N/A

    Key Differentiators

    • Oncology

  • #4

    University of Frankfurt
    University of Frankfurt

    Frankfurt, Hesse

    Key Differentiators

    • Oncology

  • #5

    International Breast Cancer Center
    International Breast Cancer Center

    N/A, N/A

    Key Differentiators

    • Oncology

Original Source(s)

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

  • by Peter Schmid, Seock-Ah Im, Zbigniew Nowecki, Piotr J. Wysocki, Jacek Jassem, Kyung Hae Jung, Simon Lord, Jon Armstrong, Ross Stewart, Petra Vuković, Neelima Denduluri, Yeon Hee Park

  • June 8, 2026

Related Content

Association between tumor genomic mutations and the risk of PD-1 inhibitor-induced hypophysitis: a retrospective cohort study

Integrating In silico perturbation with multilayer omics to decode regulatory networks in cancer immunity: a new frontier in precision oncology

Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial